----

----

| New York                                                            |   | 13-2538207                               |
|---------------------------------------------------------------------|--------|------------------------------------------|
| (State      or other jurisdiction of incorporation or organization) |   | (I.R.S      Employer Identification No.) |
|                                                                |   |                                     |
| 420 Lexington Ave. Ste 212, New      York                           |   | 10170                                    |
| (Address      of principle executive office)                        |   | (Zip      Code)                          |

| Issuer’s      telephone number | 212-687-1050 |
|--------------------------------------|--------------|

| Class                             |   | Outstanding January 7,  2009 |
|-----------------------------------|--------|------------------------------|
| Common      Stock $.001 par value |   | 30,943,450                   |

| Large      accelerated filer £ | Accelerated      filer £ | Non-accelerated      filer £ | Smaller      reporting company T |
|-------------------------------------|-------------------------------|-----------------------------------|----------------------------------|

----

----

----

|                                                                                                                               |   | November 30,      2008 |        |   | May 31,      2008 |   |
|------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------|-------------|--------|------------------------|--------|
|                                                                                                                               |   | (UNAUDITED)                 |        |   | (AUDITED)              |   |
|                                                                                                                               |   |                        |        |   |                   |   |
| Current      assets:                                                                                                               |   |                        |        |   |                   |   |
| Cash      and cash equivalents                                                                                                     |   | $                           | 4,701       |   |                   | $      | 38,867 |   |
| Accounts      receivable                                                                                                           |   |                        | 24,778      |   |                   |   | 82,490 |   |
| Inventory                                                                                                                          |   |                        | 212,088     |   |                   |   | 219,637 |   |
| Total      current assets                                                                                                          |   |                        | 241,567     |   |                   |   | 340,994 |   |
|                                                                                                                               |   |                        |        |   |                   |   |   |   |
| Deferred      income tax asset, net of valuation allowance of $1,485,000 and $1,435,000      at November 30, 2008 and May 31, 2008 |   |                        |        |   |                   |   |   |   |
|                                                                                                                               |   |                        |        |   |                   |   |   |   |
| Total      assets                                                                                                                  |   | $                           | 241,567     |   |                   | $      | 340,994 |   |
|                                                                                                                               |   |                        |        |   |                   |   |   |   |
| LIABILITIES      AND STOCKHOLDERS' EQUITY                                                                                          |   |                        |        |   |                   |   |   |   |
|                                                                                                                               |   |                        |        |   |                   |   |   |   |
| Currents      liabilities:                                                                                                         |   |                        |        |   |                   |   |   |   |
| Accounts      payable and accrued expenses                                                                                         |   | $                           | 224,497     |   |                   | $      | 173,506 |   |
| Shareholder      loan                                                                                                              |   |                        | 119,000     |   |                   |   | 7,000 |   |
| Deferred      revenue                                                                                                              |   |                        | 8,685       |   |                   |   | 42,722 |   |
| Deferred      license fees                                                                                                         |   |                        | 186,305     |   |                   |   | 264,477 |   |
| Total      liabilities                                                                                                             |   |                        | 538,487     |   |                   |   | 487,705 |   |
|                                                                                                                               |   |                        |        |   |                   |   |   |   |
|                                                                                                                               |   |                        |        |   |                   |   |   |   |
|                                                                                                                               |   |                        |        |   |                   |   |   |   |
| Stockholders'      deficit                                                                                                         |   |                        |        |   |                   |   |   |   |
| Convertible      preferred stock                                                                                                   |   |                        | 1,840       |   |                   |   | 1,840 |   |
| Common      stock                                                                                                                  |   |                        | 30,943      |   |                   |   | 30,943 |   |
| Additional      paid-in capital                                                                                                    |   |                        | 16,617,615  |   |                   |   | 16,617,615 |   |
| Accumulated      deficit                                                                                                           |   |                        | (16,947,318 | )      |                   |   | (16,797,109 | ) |
| Stockholders'      deficit                                                                                                         |   |                        | (296,920    | )      |                   |   | (146,711 | ) |
| Total      liabilities and stockholders' deficit                                                                                   |   | $                           | 241,567     |   |                   | $      | 340,994 |   |

----

|                                              |   | (UNAUDITED)For      the three months Ended      November 30, |       |   | (UNAUDITED)For      the six months Ended      November 30, |   |
|---------------------------------------------------|--------|-------------------------------------------------------------------|------------|--------|-----------------------------------------------------------------|--------|
|                                              |   |                                                              |       |   |                                                            |   |   |   |   |   |   |   |
|                                              |   | 2008                                                              |       |   | 2007                                                            |   |   | 2008 |   |   | 2007 |   |
|                                              |   |                                                              |       |   |                                                            |   |   |   |   |   |   |   |
| Total      revenues                               |   |                                                              | 99,677     |   |                                                            |   | 188,093 |   |   |   | 220,064 |   |   |   | 410,326 |   |
|                                              |   |                                                              |       |   |                                                            |   |   |   |   |   |   |   |   |   |   |   |
| Costs      and expenses:                          |   |                                                              |       |   |                                                            |   |   |   |   |   |   |   |   |   |   |   |
| Cost      of sales                                |   |                                                              | 12,168     |   |                                                            |   | 27,749 |   |   |   | 30,167 |   |   |   | 56,656 |   |
| Salaries                                          |   |                                                              | 48,542     |   |                                                            |   | 65,446 |   |   |   | 116,420 |   |   |   | 133,183 |   |
| Professional      fees and consulting             |   |                                                              | 55,610     |   |                                                            |   | 40,758 |   |   |   | 99,917 |   |   |   | 87,701 |   |
| Rent      and office expense                      |   |                                                              | 26,953     |   |                                                            |   | 36,145 |   |   |   | 58,696 |   |   |   | 68,609 |   |
| Travel      and meetings                          |   |                                                              | 1,345      |   |                                                            |   | 38,084 |   |   |   | 6,073 |   |   |   | 66,298 |   |
| Insurance                                         |   |                                                              | 39,965     |   |                                                            |   | 29,733 |   |   |   | 47,243 |   |   |   | 38,172 |   |
| Other      administrative expenses                |   |                                                              | 4,655      |   |                                                            |   | 2,256 |   |   |   | 11,757 |   |   |   | 5,244 |   |
| Total      costs and expenses                     |   |                                                              | 189,238    |   |                                                            |   | 240,171 |   |   |   | 370,273 |   |   |   | 455,863 |   |
|                                              |   |                                                              |       |   |                                                            |   |   |   |   |   |   |   |   |   |   |   |
| Net      loss                                     |   | $                                                                 | (89,561    | )      |                                                            | $      | (52,078 | ) |   | $ | (150,209 | ) |   | $ | (45,537 | ) |
|                                              |   |                                                              |       |   |                                                            |   |   |   |   |   |   |   |   |   |   |   |
| Net      loss per share – basic and diluted |   | $                                                                 | (0.00      | )      |                                                            | $      | (0.00 | ) |   | $ | (0.00 | ) |   | $ | (0.00 | ) |
|                                              |   |                                                              |       |   |                                                            |   |   |   |   |   |   |   |   |   |   |   |
| Weighted      average number of common            |   |                                                              |       |   |                                                            |   |   |   |   |   |   |   |   |   |   |   |
| Shares      outstanding – basic and diluted |   |                                                              | 30,943,450 |   |                                                            |   | 30,943,450 |   |   |   | 30,943,450 |   |   |   | 30,943,450 |   |

----

|                                                                                  |   | (UNAUDITED)For      the six months Ended November 30, |     |
|---------------------------------------------------------------------------------------|--------|------------------------------------------------------------|----------|
|                                                                                  |   |                                                       |     |   |   |   |
|                                                                                  |   | 2008                                                       |     |   | 2007 |   |
|                                                                                  |   |                                                       |     |   |   |   |
| Cash      flows from operating activities:                                            |   |                                                       |     |   |   |   |
| Net      loss                                                                         |   | $                                                          | (150,209 | ) |   | $ | (45,537 | ) |
| Adjustments      to reconcile net loss to net cash used in operating      activities: |   |                                                       |     |   |   |   |   |   |
| Changes      in operating assets and liabilities                                      |   |                                                       |     |   |   |   |   |   |
| Decrease      (increase) in accounts receivable                                       |   |                                                       | 57,712   |   |   |   | (189,084 | ) |
| Decrease      in inventory                                                            |   |                                                       | 7,549    |   |   |   | 18,308 |   |
| Increase      (decrease) in accounts payable and accrued expenses                     |   |                                                       | 50,991   |   |   |   | (6,091 | ) |
| Decrease      in deferred revenue                                                     |   |                                                       | (34,037  | ) |   |   | - |   |
| Decrease      in deferred license fees                                                |   |                                                       | (78,172  | ) |   |   | (105,205 | ) |
| Net      cash flows used in operating activities                                      |   |                                                       | (146,166 | ) |   |   | (327,609 | ) |
|                                                                                  |   |                                                       |     |   |   |   |   |   |
| Cash      flows from financing activities:                                            |   |                                                       |     |   |   |   |   |   |
| Increase      in shareholder loan                                                     |   |                                                       | 112,000  |   |   |   | - |   |
| Cash      provided by financing activities                                            |   |                                                       | 112,000  |   |   |   | - |   |
|                                                                                  |   |                                                       |     |   |   |   |   |   |
| Decrease      in cash                                                                 |   |                                                       | (34,166  | ) |   |   | (327,609 | ) |
|                                                                                  |   |                                                       |     |   |   |   |   |   |
| Cash      - Beginning of Period                                                       |   |                                                       | 38,867   |   |   |   | 413,569 |   |
|                                                                                  |   |                                                       |     |   |   |   |   |   |
| Cash      – End of Period                                                       |   | $                                                          | 4,701    |   |   | $ | 85,960 |   |

----

----

|   | - | Smith      and Nephew continues to distribute the Catrix Wound Dressing in Spain      under a sublicensing Agreement concluded in July  2007. |
|--------|---|-----------------------------------------------------------------------------------------------------------------------------------------------|

|   | - | In      Korea, Daewoong Pharmaceutical is conducting further toxicity tests on the      Catrix Wound Dressing to meet regulatory requirements of the Korean      FDA. |
|--------|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | - | In      Thailand, under an agreement signed in February, 2008, NANO Asia is      preparing to distribute the Catrix Wound Dressing as it works to meet      regulatory requirements. |
|--------|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 31 | Certification      pursuant to Exchange Act Rule 13a – 14  (a)/15d-14(a) |
|--------|----|--------------------------------------------------------------------------------|

|   | 32 | Certification      pursuant to 18 U.S.C. Section 1350 as adopted pursuant to section 906 of      the Sarbanes-Oxley Act of 2002 |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------|

|                        | LESCARDEN INC. |
|-----------------------------|----------------|
|                        | (Registrant)   |
|                        |           |   |
|                        |           |   |
| Date:      January 14, 2009 |           |   |
|                        |           |   |
|                        | S/   | William E. Luther |
|                        |           | William      E. Luther |
|                        |           | Chief      Executive Officer and |
|                        |           | Chief      FinancialOfficer |

----